Ian Glaspole

11.0k total citations · 2 hit papers
131 papers, 6.4k citations indexed

About

Ian Glaspole is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Epidemiology. According to data from OpenAlex, Ian Glaspole has authored 131 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Pulmonary and Respiratory Medicine, 26 papers in Physiology and 16 papers in Epidemiology. Recurrent topics in Ian Glaspole's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (112 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (32 papers) and Sarcoidosis and Beryllium Toxicity Research (24 papers). Ian Glaspole is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (112 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (32 papers) and Sarcoidosis and Beryllium Toxicity Research (24 papers). Ian Glaspole collaborates with scholars based in Australia, United States and United Kingdom. Ian Glaspole's co-authors include Lisa Lancaster, Marilyn K. Glassberg, Steven D. Nathan, David J. Lederer, Paul W. Noble, Carlos A. Pereira, Jeffrey J. Swigris, Williamson Z. Bradford, Elizabeth A. Fagan and Talmadge E. King and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ian Glaspole

124 papers receiving 6.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

2014 2.6k citations Ian Glaspole, Peter Hopkins et al. profile →
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials

2015 320 citations Ian Glaspole et al. European Respiratory Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ian Glaspole Australia	32	5.6k	1.8k	659	646	519	131	6.4k
Elena Bargagli Italy	39	3.4k 0.6×	1.9k 1.1×	542 0.8×	390 0.6×	451 0.9×	286	5.0k
Wim Wuyts Belgium	39	4.1k 0.7×	1.6k 0.9×	642 1.0×	412 0.6×	378 0.7×	199	5.3k
Paolo Spagnolo Italy	45	4.7k 0.9×	2.2k 1.2×	917 1.4×	552 0.9×	361 0.7×	179	6.2k
Fabrizio Luppi Italy	34	2.6k 0.5×	1.1k 0.6×	601 0.9×	261 0.4×	166 0.3×	123	3.5k
Jin Woo Song South Korea	35	3.8k 0.7×	1.5k 0.8×	963 1.5×	441 0.7×	345 0.7×	193	4.5k
Soo‐Taek Uh South Korea	29	1.4k 0.2×	1.4k 0.8×	257 0.4×	178 0.3×	130 0.3×	152	3.2k
Graziella Turato Italy	39	4.8k 0.9×	3.8k 2.1×	412 0.6×	64 0.1×	269 0.5×	94	6.9k
Elizabeth A. Fagan United Kingdom	21	3.1k 0.6×	1.0k 0.6×	1.1k 1.6×	433 0.7×	277 0.5×	51	4.3k
S. Jouneau France	35	1.6k 0.3×	573 0.3×	758 1.2×	239 0.4×	161 0.3×	166	3.0k
Shinichi Ishioka Japan	33	1.5k 0.3×	1.4k 0.8×	550 0.8×	137 0.2×	311 0.6×	179	4.7k

Countries citing papers authored by Ian Glaspole

Since Specialization

Citations

This map shows the geographic impact of Ian Glaspole's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Glaspole with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Glaspole more than expected).

Fields of papers citing papers by Ian Glaspole

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian Glaspole. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Glaspole. The network helps show where Ian Glaspole may publish in the future.

Co-authorship network of co-authors of Ian Glaspole

This figure shows the co-authorship network connecting the top 25 collaborators of Ian Glaspole. A scholar is included among the top collaborators of Ian Glaspole based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian Glaspole. Ian Glaspole is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Holland, Anne E., Mariana Hoffman, Tamera J. Corte, et al.. (2025). Ambulatory Oxygen for Treatment of Exertional Hypoxaemia in Pulmonary Fibrosis (PFOX Trial): A Randomised Sham-Controlled Trial. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A2907–A2907.

Tan, Dino B.A., Wendy A. Cooper, Helen E. Jo, et al.. (2025). Pre‐Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients. Respirology. 30(6). 504–514. 2 indexed citations

Yang, Nan, Francesco Federico, Stephen M. Humphries, et al.. (2025). Prognostication in patients with idiopathic pulmonary fibrosis using quantitative airway analysis from HRCT: a retrospective study. European Respiratory Journal. 66(4). 2500981–2500981.

Mackintosh, John A., Gregory J. Keir, Lauren Troy, et al.. (2024). Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision. Respirology. 29(2). 105–135. 26 indexed citations

West, Alex, Nazia Chaudhuri, Adam Barczyk, et al.. (2023). Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial. Thorax. 78(9). 882–889. 35 indexed citations

Zheng, Qiang, Lucy Leigh, Barbara de Graaff, et al.. (2023). Long‐term exposure to low concentrations of air pollution and decline in lung function in people with idiopathic pulmonary fibrosis: Evidence from Australia. Respirology. 28(10). 916–924. 13 indexed citations

Hoffman, Mariana, et al.. (2021). Pulmonary rehabilitation for interstitial lung disease: Referral and patient experiences. Chronic Respiratory Disease. 18. 4053470342–4053470342. 13 indexed citations

Tikellis, Gabriella, Tamera J. Corte, Alan Teoh, et al.. (2021). Barriers and facilitators to best care for idiopathic pulmonary fibrosis in Australia. Respirology. 27(1). 76–84. 10 indexed citations

Tikellis, Gabriella, Joanna Y.T. Lee, Tamera J. Corte, et al.. (2020). Peer Connect Service for people with pulmonary fibrosis in Australia: Participants' experiences and process evaluation. Respirology. 25(10). 1053–1059. 10 indexed citations

10.

Lee, Joanna Y.T., Gabriella Tikellis, Tamera J. Corte, et al.. (2020). The supportive care needs of people living with pulmonary fibrosis and their caregivers: a systematic review. European Respiratory Review. 29(156). 190125–190125. 54 indexed citations

11.

Holland, Anne E., Tamera J. Corte, Daniel C. Chambers, et al.. (2020). Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX trial): a randomised controlled trial. BMJ Open. 10(12). e040798–e040798. 12 indexed citations

12.

Holland, Anne E., et al.. (2019). Comprehensive pulmonary rehabilitation for interstitial lung disease: A consensus approach to identify core education topics. Patient Education and Counseling. 102(6). 1125–1130. 24 indexed citations

13.

Montgomery, A. Bruce, et al.. (2019). A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 33(1). 15–20. 30 indexed citations

14.

Glaspole, Ian, et al.. (2018). Understanding the patient's experience of care in idiopathic pulmonary fibrosis. Respirology. 24(3). 270–277. 28 indexed citations

15.

Wilcox, Pearce, Ian Glaspole, Tamera J. Corte, et al.. (2017). Cough is less common and less severe in systemic sclerosis‐associated interstitial lung disease compared to other fibrotic interstitial lung diseases. Respirology. 22(8). 1592–1597. 31 indexed citations

16.

Khor, Yet H., Christine F. McDonald, Karen Symons, et al.. (2017). Portable oxygen concentrators versus oxygen cylinder during walking in interstitial lung disease: A randomized crossover trial. Respirology. 22(8). 1598–1603. 16 indexed citations

17.

Dowman, Leona, Christine F. McDonald, Catherine J. Hill, et al.. (2017). The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. Thorax. 72(7). 610–619. 196 indexed citations

18.

Holland, Anne E., Julio F. Fiore, Emily C. Bell, et al.. (2014). Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology. 19(8). 1215–1221. 110 indexed citations

19.

Holland, Anne E., Catherine J. Hill, Ian Glaspole, Nicole Goh, & Christine F. McDonald. (2011). Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respiratory Medicine. 106(3). 429–435. 98 indexed citations

20.

Glaspole, Ian, Matthew Conron, & R M du Bois. (2000). Clinical features of diffuse parenchymal lung disease. 5(14). 1–14. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact